metabolic syndrome
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Waist circumference: 85 cm or greater plus positive at least 2 factors below. 1) fasting glucose, 110 mg/dl or higher 2) HDL-cholesterol, less than 40 mg/dl and/or triglyceride, 150 mg/dl or higher 3) systolic blood pressure, 130 mmHg or higher and/or diastolic blood pressure, 85 mmHg or higher * Those on medication for diabetes or hypertension are regarded as positive for the corresponding item, whereas those on medication on hyperlipidemia are not.
Exclusion criteria
Exclusion criteria: a) Persons with a history of cerebrovascular diseases, myocardial infarction, cancer, or other severe diseases. b) Persons on medical treatment for diabetes or those who have fasting glucose of 140 mg/dl or higher c) Persons with systolic blood pressure of 180 mmHg or higher and/or diastolic blood pressure of 110 mmHg or higher, or with triglyceride of 1000 mg/dl or higher d) Persons who can not do exercise due to musculoskeletal problem e) Persons who have no intention or are unable to improve their lifestyle f) Persons who can not participate follow-up surveys g) Persons in conditions that are judged as ineligible by a occupational physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The prevalence of metabolic syndrome at 6 month | — |
Secondary
| Measure | Time frame |
|---|---|
| (Changes between baseline and 6 month) 1) waist circumference, body weight, body mass index, systolic blood pressure, diastolic blood pressure, glucose, HDL cholesterol, triglyceride 2) diet: energy-adjusted intakes of vegetables, fruits, dairy foods (milk), dietary fiber, calcium, magnesium, and folate. Alcohol consumption. 3) Changes of physical activity: weekly hours or MET-hours of activities on leisure-time and transportation from home to work 4) Prevalence of smoking 5) Biochemical parameters:(blood) hemoglobin A1c, C-peptide, high-sensitivity C-reactive protein, IL-6, adiponectin, vitamin D, folate, homocysteine, alpha- and beta-carotenes, insulin-like growth factor-I (IGF-I), insulin-like growth factor binding protein 1 (IGFBP-1), insulin-like growth factor binding protein-3 (IGFBP-3), fatty acid composition, (urine) 8-hydroxydeoxyguanosine, isoprostane 6) depression score(CES-D) 7) Changes of the above items at 1 year | — |
Countries
Japan
Contacts
International Medical Center of Japan, Research Institute Department of Epidemiology and International Health